Please use this identifier to cite or link to this item:
Title: Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy
Authors: Goh, Wei Jiang
Lee, Choon Keong
Zou, Shui
Woon, Esther
Czarny, Bertrand
Pastorin, Giorgia
Keywords: Cell-derived nanovesicles
Cell targeting
Issue Date: 2017
Source: Goh, W. J., Lee, C. K., Zou, S., Woon, E., Czarny, B., & Pastorin, G. (2017). Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy. International Journal of Nanomedicine, 12, 2759-2767.
Series/Report no.: International Journal of Nanomedicine
Abstract: Cell-derived nanovesicles (CDNs) are an emerging class of biological drug delivery systems (DDS) that retain the characteristics of the cells they were derived from, without the need for further surface functionalization. CDNs are also biocompatible, being derived from natural sources and also take advantage of the enhanced permeability and retention effect due to their nanodimensions. Furthermore, CDNs derived from monocytes were shown to have an in vivo targeting effect, accumulating at the tumor site in a previous study conducted in a mouse tumor model. Here, we report a systematic approach pertaining to various loading methods of the chemotherapeutic drug doxorubicin into our CDNs and examine the differential cellular uptake of drug-loaded CDNs in cancerous (HeLa) and healthy (HEK293) cell lines. Lastly, we proved that the addition of doxorubicin-loaded CDNs to the HeLa and HEK293 co-cultures showed a clear discrimination toward cancer cells at the cellular level. Our results further reinforce the intriguing potential of CDNs as an alternative targeted strategy for anticancer therapy.
ISSN: 1176-9114
DOI: 10.2147/IJN.S131786
Rights: © 2017 Goh et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles
MSE Journal Articles

Citations 10

Updated on Mar 10, 2021

Citations 10

Updated on Mar 3, 2021

Page view(s) 50

Updated on Jun 23, 2022

Download(s) 50

Updated on Jun 23, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.